about
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsPrediction of Genetic Interactions Using Machine Learning and Network PropertiesImproved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmInsights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.XAV939-mediated ARTD activity inhibition in human MB cell lines.Krüppel-like factor 8 emerges as an important regulator of cancerChromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1α, autophagy and ketone body productionOvarian cancer: in search of better marker systems based on DNA repair defectsThe role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapyMolecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancerPARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?The Ensembl Variant Effect Predictor.New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Olaparib: a promising PARP inhibitor in ovarian cancer therapy.Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.Generation of small molecules to interfere with regulated necrosis.The antiproliferative and apoptotic effects of apigenin on glioblastoma cells.The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells.Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins.Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.Ampulla of vater adenocarcinoma in a BRCA2 germline mutation carrierPharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancerPatterns and mechanisms of structural variations in human cancer
P2860
Q26852274-20FB3C9B-3D14-4406-915F-24105A03CD90Q28084302-B8F6C9FA-AC7E-45EB-9C0D-21564C689EF2Q33731278-7AE27705-9CD2-4A39-BB2F-747EF7038DD4Q34299288-0B99E028-F372-45DE-AEAA-6A108339C94BQ35395549-5FC07951-7098-44C8-B357-9C7DFBC02202Q35593198-DA6CB108-2332-466C-942E-49A94871001AQ36185362-69E47137-D60F-413F-BCBE-736F4B16175BQ36193912-676CBD3D-707F-4916-87A5-1EB2932752F3Q36235684-C30316AE-9FF7-464D-9254-35F7642FB5EAQ36472238-5B353F40-282A-4729-B3D5-904D0E6426D1Q36589947-3E62628E-30CD-464B-B06C-BF2C2695FB7DQ36689932-BC1E3A17-6304-4FF2-B989-98CA04D973F9Q36697860-28F4B66D-76D5-46FB-A8D1-BDEBD929FC89Q36740692-3C6BF02F-CCF9-41D2-B81B-CF5BF58434CFQ36854062-100A60DB-CE11-4C61-8E88-9D4390EC9DE5Q36860835-EDC756A4-6FFF-4582-BFC9-653E3CC4F546Q36970975-321BFBE0-8E43-48C1-984B-C27B5E0605E3Q37155964-0B1A15CB-80DC-45CA-89D5-194F44229E96Q37631514-34B8A564-916B-4A69-8A9B-152CDF501884Q37712074-E4736D74-8A1D-42E9-899D-82E0047A4276Q38023238-4307EC9A-8BAA-4177-89A1-EC1E6AAC0E27Q38101861-B6ADFADF-8544-4D66-8A89-AC5750C8BA82Q38248418-A9E83270-C536-4204-BC76-C6E5D552B9CCQ38789039-EF8C3B64-DA4C-4886-A318-1A04C6F922B8Q38799144-C22423E2-6F1C-48CA-9296-5E64A7C77FA4Q38871823-295A49E5-925E-4DF7-A904-19FD78B4AF9AQ39310326-2B5EC564-7BE0-4865-989D-7890651175C0Q42055866-B0B49534-53A7-4401-845F-8C090842C13EQ42107975-DD01F81D-CD67-411F-869B-6A201F7850ADQ42378380-F4F067C6-3A78-4B88-A9B7-3790024222A4Q42561379-B37253A2-78DD-4DB9-BA19-A73CF94B37F3Q43655173-BEBC097A-F3D9-4623-A513-4F31621E169AQ45213264-B077996E-B8F7-45BC-8273-EDDA621A36E3Q46538042-FAB3A1E1-35DA-413E-A7F4-8B78BBD09A08Q48242157-EC073C37-92B8-4BBB-A02B-CED1E9562FD4Q48535740-B7E90D9A-CAFE-448E-B8E8-E8216CBEB64BQ49852384-E8EC3FD3-A7C6-4730-A3E5-481784F49349Q57153805-2717D1BC-2B9D-41F7-95C8-08DDE5828E96Q58692184-F51F491A-1683-4A17-A3D5-079BC7A9281FQ58797497-06940177-FFED-4CE7-A7DD-322399B5CC9B
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
PARP inhibitor treatment in ovarian and breast cancer
@ast
PARP inhibitor treatment in ovarian and breast cancer
@en
PARP inhibitor treatment in ovarian and breast cancer
@nl
type
label
PARP inhibitor treatment in ovarian and breast cancer
@ast
PARP inhibitor treatment in ovarian and breast cancer
@en
PARP inhibitor treatment in ovarian and breast cancer
@nl
prefLabel
PARP inhibitor treatment in ovarian and breast cancer
@ast
PARP inhibitor treatment in ovarian and breast cancer
@en
PARP inhibitor treatment in ovarian and breast cancer
@nl
P2860
P3181
P1476
PARP inhibitor treatment in ovarian and breast cancer
@en
P2093
Alice P Chen
Marcie K Weil
P2860
P3181
P356
10.1016/J.CURRPROBLCANCER.2010.12.002
P407
P577
2011-01-01T00:00:00Z